Literature DB >> 22331072

[Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options].

U Mehnert1, M Nehiba.   

Abstract

The lower urinary tract (LUT) is regulated by a complex neural network that is subject to supraspinal control. Neurological disorders, especially of the central nervous system (CNS), can rapidly lead to disruption of this control. Multiple sclerosis, Parkinson's disease, multiple system atrophy, and stroke are neurological disorders which quite frequently cause dysfunction of the LUT. With respect to the pathophysiology of bladder dysfunction in CNS diseases there are various hypotheses regarding the individual disorders: disturbances of neural communication between the frontal cortex and pontine micturition center, between the pontine micturition center and the lumbosacral parts of the spinal cord, and between the basal ganglia, thalamus, and anterior cingulate gyrus appear to play a pivotal role in the development of bladder dysfunction. The symptoms and urodynamic presentation of LUT dysfunction can vary considerably depending on the disease and disease progression and can change in the course of the disease. The incidence and prevalence of LUT dysfunctions rise with increasing progression of the underlying neurological disease.Various conservative, minimally invasive, and open surgical procedures are available to prevent harmful sequelae and to improve the quality of life of these patients. As yet, however, few data exist on most of the treatment options in cases of the above-mentioned CNS diseases. Intermittent self-catheterization and antimuscarinic medications are among the most important conservative treatment options. Injection of botulinum neurotoxin type A into the detrusor muscle and increasingly sacral or pudendal neuromodulation are among the most important minimally invasive treatment options. Surgical methods include reconstructive continent or incontinent urinary diversion.When planning therapy the patient's current needs and neurological limitations as well as possible disease progression must be taken into consideration. It is often advisable to consult with and enlist the cooperation of the attending neurologist when planning treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22331072     DOI: 10.1007/s00120-011-2796-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  71 in total

1.  Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis.

Authors:  Adélia Correia Lúcio; Renata Martins Campos; Maria Carolina Perissinotto; Ricardo Miyaoka; Benito Pereira Damasceno; Carlos Arturo Levi D'ancona
Journal:  Neurourol Urodyn       Date:  2010-11       Impact factor: 2.696

2.  Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia.

Authors:  Frédéric Bloch; Bertrand Pichon; Anne-Marie Bonnet; Jacques Pichon; Marie Vidailhet; Emmanuel Roze; Michel Perrigot
Journal:  J Neurol       Date:  2010-08-04       Impact factor: 4.849

3.  Tension-free vaginal tape for the treatment of urodynamic stress incontinence with intrinsic sphincteric deficiency.

Authors:  Fabio Ghezzi; Maurizio Serati; Antonella Cromi; Stefano Uccella; Stefano Salvatore; Paola Triacca; Pierfrancesco Bolis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-10-07

4.  Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score.

Authors:  I Araki; S Kuno
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

5.  Is there a long-lasting effect of pelvic floor muscle training in women with urinary incontinence after ischemic stroke? A 6-month follow-up study.

Authors:  S Tibaek; G Gard; R Jensen
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-06-28

6.  Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage.

Authors:  M Horstmann; T Schaefer; Y Aguilar; A Stenzl; K D Sievert
Journal:  Neurourol Urodyn       Date:  2006       Impact factor: 2.696

Review 7.  Cranberry and urinary tract infections.

Authors:  David R P Guay
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  A UK consensus on the management of the bladder in multiple sclerosis.

Authors:  C J Fowler; J N Panicker; M Drake; C Harris; S C W Harrison; M Kirby; M Lucas; N Macleod; J Mangnall; A North; B Porter; S Reid; N Russell; K Watkiss; M Wells
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-05       Impact factor: 10.154

Review 9.  The immunology of multiple sclerosis.

Authors:  Amit Bar-Or
Journal:  Semin Neurol       Date:  2008-02       Impact factor: 3.420

10.  Botulinum injections for the treatment of bladder symptoms of multiple sclerosis.

Authors:  Vinay Kalsi; Gwen Gonzales; Roshni Popat; Apostolos Apostolidis; Sohier Elneil; Prokar Dasgupta; Clare J Fowler
Journal:  Ann Neurol       Date:  2007-11       Impact factor: 10.422

View more
  1 in total

1.  [Urodynamic classification of male patients with symptoms of overactive bladder and the outcome classification].

Authors:  T Wang; K X Xu; W Y Zhang; H Hu; X W Zhang; H R Wang; X H Liu; J W Chen; X P Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.